Posts Tagged ‘034’
Extended-release buprenorphine induction in opioid non-tolerant incarcerated individuals
Buprenorphine maintenance treatment remains unavailable in most jails in the US. We provide data on a four-day rapid sublingual buprenorphine (SL-B) induction strategy followed by a weekly dose of extended release injectable buprenorphine (XR-B) with incarcerated individuals with opioid use disorder (OUD) who were not opioid tolerant.
Read MoreA clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail
This proposed randomized control trial will test the pharmacotherapy adherence (number of monthly injections received) of extended-release buprenorphine (XR-B) versus extended-release naltrexone (XR-NTX) among adults with opioid use disorder (OUD) who are nearing release from county jails in Maryland. The results of this trial will have substantial public health implications as most individuals with OUD…
Read MoreXR:NTX vs XR:B (Brixadi) (034)
This study is conducting a comparative effectiveness trial of extended-release naltrexone (XR-NTX) versus a new extended-release formulation of buprenorphine (Brixadi, XR-B) to treat opioid use disorder (OUD) among justice-involved individuals in ten Maryland county jails.
Participants will be randomly assigned to receive either XR-NTX or XR-B prior to release from jail, followed by six monthly injections while in the community. The goal of the study is to evaluate the effectiveness of the two medications, measure medication adherence, and gather data to inform broader scale-up of medications for opioid use disorder (MOUD) in jails and in the community.
Read More